Literature DB >> 17526980

Feasibility and safety of transradial stenting for unprotected left main coronary artery stenoses.

Cheng-I Cheng1, Chiung-Jen Wu, Chih-Yuan Fang, Ali A Youssef, Chien-Jen Chen, Shyh-Ming Chen, Cheng-Hsu Yang, Shu-Kai Hsueh, Hon-Kan Yip, Mien-Cheng Chen, Morgan Fu, Yuan-Kai Hsieh.   

Abstract

BACKGROUND: Percutaneous coronary intervention (PCI) is considered an excellent alternative treatment for unprotected left main coronary artery (ULMCA) stenoses. Most PCIs for ULMCA stenoses are performed via the transfemoral approach. The feasibility and safety of the transradial approach for this particular entity are unknown. The present study assessed the feasibility, safety and 1-year outcomes of the transradial approach for stenting of ULMCA stenoses. METHODS AND
RESULTS: Of 131 consecutive patients who underwent coronary stenting for ULMCA stenoses, 113 patients (86.3%) received stenting using the transradial approach. All 113 procedures were performed with 6 or 7 French (Fr) catheters except 1 procedure requiring an 8 Fr guiding catheter for directional atherectomy. The technical success rate was 100%, and angiographic success was achieved in 96 patients (85.9%). Two patients had local hematoma (1.8%), and no procedure-related deaths, Q-wave myocardial infarction, repetitive PCI, stroke or emergent coronary artery bypass graft surgery during hospitalization were noted. One (0.9%) in-hospital cardiac death occurred due to ventricular tachyarrhythmia. More than half of our patients stayed in hospital by < or =3 days. The 1-year target lesion revascularization and cardiac death rate were 14.2% and 3.5%, respectively.
CONCLUSIONS: This investigation demonstrated the feasibility, safety and accepted short-term clinical outcomes of transradial stenting for ULMCA stenosis. This procedure may offer a feasible alternative to the transfemoral approach.

Entities:  

Mesh:

Year:  2007        PMID: 17526980     DOI: 10.1253/circj.71.855

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis.

Authors:  Sanjay B Pandya; Young-Hak Kim; Sheridan N Meyers; Charles J Davidson; James D Flaherty; Duk-Woo Park; Anuj Mediratta; Karen Pieper; Eric Reyes; Robert O Bonow; Seung-Jung Park; Nirat Beohar
Journal:  JACC Cardiovasc Interv       Date:  2010-06       Impact factor: 11.195

2.  Transradial percutaneous coronary intervention for chronic total occlusion of coronary artery disease using sheathless standard guiding catheters.

Authors:  Huang-Chung Chen; Wei-Chieh Lee; Shu-Kai Hsueh; Cheng-I Cheng; Chien-Jen Chen; Cheng-Hsu Yang; Chih-Yuan Fang; Chi-Ling Hang; Hon-Kan Yip; Chiung-Jen Wu; Hsiu-Yu Fang
Journal:  Int J Cardiol Heart Vasc       Date:  2014-12-30

3.  Residual Right Coronary Artery Stenosis after Left Main Coronary Artery Intervention Increased the 30-Day Cardiovascular Death and 3-Year Right Coronary Artery Revascularization Rate.

Authors:  Chien-Ho Lee; Shaur-Zheng Chong; Shu-Kai Hsueh; Wen-Jung Chung; Cheng-I Cheng
Journal:  J Interv Cardiol       Date:  2020-06-14       Impact factor: 2.279

4.  Advantages of Transradial Rotational Atherectomy versus Transfemoral Approach in Elderly Patients with Hard-Handling Calcified Coronary Lesions - A Single Center Experience.

Authors:  Wei You; Xiang-Qi Wu; Fei Ye; Shao-Liang Chen
Journal:  Acta Cardiol Sin       Date:  2018-11       Impact factor: 2.672

5.  Safety and technical success of percutaneous left main coronary artery stenting.

Authors:  Liaqat Ali; Shahid Nawaz Malik; Abdullah Bin Khalid; Mehboob Sultan; Nadeem Sadiq
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

6.  Two-year clinical outcomes in stable angina and acute coronary syndrome after percutaneous coronary intervention of left main coronary artery disease.

Authors:  Dae Young Hyun; Myung Ho Jeong; Doo Sun Sim; Yun Ah Jeong; Kyung Hoon Cho; Min Chul Kim; Hyun Kuk Kim; Hae Chang Jeong; Keun Ho Park; Young Joon Hong; Jun Han Kim; Youngkeun Ahn; Jung Chaee Kang
Journal:  Korean J Intern Med       Date:  2016-10-18       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.